Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis

L. Gulácsi, Zsombor Zrubka, Valentin Brodszky, Fanni Rencz, Rieke Alten, Z. Szekanecz, Márta Péntek

Research output: Contribution to journalArticle

Abstract

Introduction: Synthesis of evidence on the long-term use of first-line biologic therapy in patients with early rheumatoid arthritis (RA) is required. We compared the efficacy of up to 5 years’ treatment with first-line tumor necrosis factor inhibitors (TNFis) versus other treatment strategies in this population. Methods: Previous systematic reviews, PubMed and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) involving treatment of methotrexate-naïve RA patients with first-line TNFis. Literature was synthesized qualitatively, and a meta-analysis conducted to evaluate American College of Rheumatology (ACR) responses, clinical remission defined by any standard measure, and Health Assessment Questionnaire Disability Index (HAQ) at Years 2 and/or 5. Results: Ten RCTs involving 4306 patients [first-line TNFi, n = 2234; other treatment strategies (control), n = 2072] were included in the meta-analysis. Three studies were double-blind for the first 2 years, while seven were partly/completely open label during this period. Five studies reported data at Year 5; all were open label at this time point. At Year 2, ACR50 response, ACR70 response and remission rates were significantly improved with first-line TNFi versus control in double-blind RCTs [log-odds ratio (OR) 0.32 [95% confidence interval (CI) 0.02, 0.62; p = 0.035], log-OR 0.48 (95% CI 0.20, 0.77; p = 0.001), and log-OR 0.44 (95% CI 0.13, 0.74; p = 0.005), respectively], but not in open-label studies. No significant between-group differences were observed in mean HAQ at Year 2 in double-blind or open-label RCTs or in ACR response or remission outcomes at Year 5. Conclusion: In double-blind studies, 2-year efficacy outcomes were significantly improved with first-line TNFi versus other treatment strategies in patients with MTX-naïve RA. No significant differences in these outcomes were observed when data from open-label RCTs were considered on their own. Further data on the efficacy of TNFi therapy over ≥ 2 years in patients with methotrexate-naïve RA are required. Plain Language Summary: Plain language summary available for this article.

Original languageEnglish
JournalAdvances in Therapy
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Methotrexate
Meta-Analysis
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
ametantrone
Randomized Controlled Trials
Odds Ratio
Confidence Intervals
Double-Blind Method
Language
Therapeutics
Biological Therapy
Rheumatology
PubMed
Health
Population

Keywords

  • Biologic
  • Disease-modifying antirheumatic drug
  • Early
  • Efficacy
  • First line
  • Meta-analysis
  • Methotrexate-naïve
  • Systematic review
  • Tumor necrosis factor inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis : Systematic Literature Review and Meta-Analysis. / Gulácsi, L.; Zrubka, Zsombor; Brodszky, Valentin; Rencz, Fanni; Alten, Rieke; Szekanecz, Z.; Péntek, Márta.

In: Advances in Therapy, 01.01.2019.

Research output: Contribution to journalArticle

@article{4a9410be34bc4368b2547d79bb0171c5,
title = "Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Na{\"i}ve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis",
abstract = "Introduction: Synthesis of evidence on the long-term use of first-line biologic therapy in patients with early rheumatoid arthritis (RA) is required. We compared the efficacy of up to 5 years’ treatment with first-line tumor necrosis factor inhibitors (TNFis) versus other treatment strategies in this population. Methods: Previous systematic reviews, PubMed and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) involving treatment of methotrexate-na{\"i}ve RA patients with first-line TNFis. Literature was synthesized qualitatively, and a meta-analysis conducted to evaluate American College of Rheumatology (ACR) responses, clinical remission defined by any standard measure, and Health Assessment Questionnaire Disability Index (HAQ) at Years 2 and/or 5. Results: Ten RCTs involving 4306 patients [first-line TNFi, n = 2234; other treatment strategies (control), n = 2072] were included in the meta-analysis. Three studies were double-blind for the first 2 years, while seven were partly/completely open label during this period. Five studies reported data at Year 5; all were open label at this time point. At Year 2, ACR50 response, ACR70 response and remission rates were significantly improved with first-line TNFi versus control in double-blind RCTs [log-odds ratio (OR) 0.32 [95{\%} confidence interval (CI) 0.02, 0.62; p = 0.035], log-OR 0.48 (95{\%} CI 0.20, 0.77; p = 0.001), and log-OR 0.44 (95{\%} CI 0.13, 0.74; p = 0.005), respectively], but not in open-label studies. No significant between-group differences were observed in mean HAQ at Year 2 in double-blind or open-label RCTs or in ACR response or remission outcomes at Year 5. Conclusion: In double-blind studies, 2-year efficacy outcomes were significantly improved with first-line TNFi versus other treatment strategies in patients with MTX-na{\"i}ve RA. No significant differences in these outcomes were observed when data from open-label RCTs were considered on their own. Further data on the efficacy of TNFi therapy over ≥ 2 years in patients with methotrexate-na{\"i}ve RA are required. Plain Language Summary: Plain language summary available for this article.",
keywords = "Biologic, Disease-modifying antirheumatic drug, Early, Efficacy, First line, Meta-analysis, Methotrexate-na{\"i}ve, Systematic review, Tumor necrosis factor inhibitor",
author = "L. Gul{\'a}csi and Zsombor Zrubka and Valentin Brodszky and Fanni Rencz and Rieke Alten and Z. Szekanecz and M{\'a}rta P{\'e}ntek",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12325-018-0869-8",
language = "English",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",

}

TY - JOUR

T1 - Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis

T2 - Systematic Literature Review and Meta-Analysis

AU - Gulácsi, L.

AU - Zrubka, Zsombor

AU - Brodszky, Valentin

AU - Rencz, Fanni

AU - Alten, Rieke

AU - Szekanecz, Z.

AU - Péntek, Márta

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Synthesis of evidence on the long-term use of first-line biologic therapy in patients with early rheumatoid arthritis (RA) is required. We compared the efficacy of up to 5 years’ treatment with first-line tumor necrosis factor inhibitors (TNFis) versus other treatment strategies in this population. Methods: Previous systematic reviews, PubMed and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) involving treatment of methotrexate-naïve RA patients with first-line TNFis. Literature was synthesized qualitatively, and a meta-analysis conducted to evaluate American College of Rheumatology (ACR) responses, clinical remission defined by any standard measure, and Health Assessment Questionnaire Disability Index (HAQ) at Years 2 and/or 5. Results: Ten RCTs involving 4306 patients [first-line TNFi, n = 2234; other treatment strategies (control), n = 2072] were included in the meta-analysis. Three studies were double-blind for the first 2 years, while seven were partly/completely open label during this period. Five studies reported data at Year 5; all were open label at this time point. At Year 2, ACR50 response, ACR70 response and remission rates were significantly improved with first-line TNFi versus control in double-blind RCTs [log-odds ratio (OR) 0.32 [95% confidence interval (CI) 0.02, 0.62; p = 0.035], log-OR 0.48 (95% CI 0.20, 0.77; p = 0.001), and log-OR 0.44 (95% CI 0.13, 0.74; p = 0.005), respectively], but not in open-label studies. No significant between-group differences were observed in mean HAQ at Year 2 in double-blind or open-label RCTs or in ACR response or remission outcomes at Year 5. Conclusion: In double-blind studies, 2-year efficacy outcomes were significantly improved with first-line TNFi versus other treatment strategies in patients with MTX-naïve RA. No significant differences in these outcomes were observed when data from open-label RCTs were considered on their own. Further data on the efficacy of TNFi therapy over ≥ 2 years in patients with methotrexate-naïve RA are required. Plain Language Summary: Plain language summary available for this article.

AB - Introduction: Synthesis of evidence on the long-term use of first-line biologic therapy in patients with early rheumatoid arthritis (RA) is required. We compared the efficacy of up to 5 years’ treatment with first-line tumor necrosis factor inhibitors (TNFis) versus other treatment strategies in this population. Methods: Previous systematic reviews, PubMed and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) involving treatment of methotrexate-naïve RA patients with first-line TNFis. Literature was synthesized qualitatively, and a meta-analysis conducted to evaluate American College of Rheumatology (ACR) responses, clinical remission defined by any standard measure, and Health Assessment Questionnaire Disability Index (HAQ) at Years 2 and/or 5. Results: Ten RCTs involving 4306 patients [first-line TNFi, n = 2234; other treatment strategies (control), n = 2072] were included in the meta-analysis. Three studies were double-blind for the first 2 years, while seven were partly/completely open label during this period. Five studies reported data at Year 5; all were open label at this time point. At Year 2, ACR50 response, ACR70 response and remission rates were significantly improved with first-line TNFi versus control in double-blind RCTs [log-odds ratio (OR) 0.32 [95% confidence interval (CI) 0.02, 0.62; p = 0.035], log-OR 0.48 (95% CI 0.20, 0.77; p = 0.001), and log-OR 0.44 (95% CI 0.13, 0.74; p = 0.005), respectively], but not in open-label studies. No significant between-group differences were observed in mean HAQ at Year 2 in double-blind or open-label RCTs or in ACR response or remission outcomes at Year 5. Conclusion: In double-blind studies, 2-year efficacy outcomes were significantly improved with first-line TNFi versus other treatment strategies in patients with MTX-naïve RA. No significant differences in these outcomes were observed when data from open-label RCTs were considered on their own. Further data on the efficacy of TNFi therapy over ≥ 2 years in patients with methotrexate-naïve RA are required. Plain Language Summary: Plain language summary available for this article.

KW - Biologic

KW - Disease-modifying antirheumatic drug

KW - Early

KW - Efficacy

KW - First line

KW - Meta-analysis

KW - Methotrexate-naïve

KW - Systematic review

KW - Tumor necrosis factor inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85060090079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060090079&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0869-8

DO - 10.1007/s12325-018-0869-8

M3 - Article

C2 - 30637590

AN - SCOPUS:85060090079

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

ER -